Home › Acute Myeloid Leukemia › NCT06279572
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy: Opportunities for T-Cell Directed Immunotherapy
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adults \> 18 yrs of age with diagnosis of acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy * Treatment naive adult acute myeloid leukemia patients Exclusion Criteria: * Acute myeloid leukemia patients receiving azacitidine and venetoclax as salvage therapy will be excluded * Patients who are pregnant or breast-feeding
About the study
This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.
What is being tested
- Biospecimen Collection (procedure)
- Bone Marrow Aspirate (procedure)
- Electronic Health Record Review (other)
Sponsor: Mayo Clinic · Participants: 80 · Started: Apr 22, 2021
Contact the study team
Official record on ClinicalTrials.gov — NCT06279572
Locations in the U.S.
| Arizona | Mayo Clinic in Arizona, Scottsdale (Not yet recruiting) |
| Florida | Mayo Clinic in Florida, Jacksonville |
| Minnesota | Mayo Clinic in Rochester, Rochester (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.